PP
ATYR

Paloma Partners’s aTyr Pharma ATYR Stock Holding History

Paloma Partners’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-733
Closed -$22K – 2278
2016
Q4 		$22K Buy
+733
New +$30.1K ﹤0.01% 1941
2016
Q3 		– Sell
-1,650
Closed -$64K – 2181
2016
Q2 		$64K Buy
+1,650
New +$76.7K ﹤0.01% 2097

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return
MCIM
Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's ATYR Position: Q1 2017 in Review

Paloma Partners sold out of aTyr Pharma (ATYR) in Q1 2017, closing a stake of 733 shares — an estimated $22K sold.

Paloma Partners first reported a position in ATYR in Q2 2016 and held it in 2 quarters. The position peaked at $64K in Q2 2016. 39 funds tracked by Wall St. Rank hold ATYR as of Q1 2017.

  • Paloma Partners reported no remaining aTyr Pharma position as of Q1 2017 after selling out during the quarter.
  • Paloma Partners sold 733 aTyr Pharma shares in Q1 2017, an estimated $22K.
  • Paloma Partners first reported a position in aTyr Pharma in Q2 2016 and held it in 2 quarters.
  • Paloma Partners's aTyr Pharma position peaked at $64K in Q2 2016.
  • 39 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2017.

Based on Paloma Partners's 13F filing for Q1 2017, filed 15 May 2017.